Is the Time Ripe to Buy Johnson & Johnson (JNJ) Stock?

If you owned Johnson & Johnson (NYSE:JNJ) stock at the beginning of 2013, you’re sitting atop gains of more than 20% right now. If you didn’t own shares of J&J, you might be wishing that you did. Is the time still ripe to buy — or has the train left the station? Let’s take a look.

Taking a breather

After a stellar start in 2013, Johnson & Johnson (NYSE:JNJ) has taken a little breather since late May. Shares have pulled back slightly.

JNJ Chart

JNJ data by YCharts.

I actually view this as a good development. The S&P 500 index also pulled back during the same period, but Johnson & Johnson (NYSE:JNJ) shares retreated by less than half as much as the broader index. This reflects solid investor support for the stock.

It’s been a while since J&J enjoyed such a nice run. The company has encountered some rough spots over the last few years, particularly with product recalls and litigation woes. These issues even resulted in Warren Buffett dumping much of his stake, saying that Johnson & Johnson (NYSE:JNJ) had made “too many mistakes.”

Johnson & Johnson (NYSE:JNJ)

Relatively speaking

Of course, J&J hasn’t been alone in climbing this year. Many blue chips have performed well in 2013 thus far. Among its peers, though, Johnson & Johnson (NYSE:JNJ) stock looks to be one of the biggest winners.

Fellow pharmaceutical giant Pfizer Inc. (NYSE:PFE) saw its shares jump more than 20% by April. However, the stock has fallen quite a bit since then. Shares are now only up less than 13%.

Similarly, Merck & Co., Inc. (NYSE:MRK) was up more than 20% for the year in early June. The stock now claims year-to-date gains of 14%.

Although its quite smaller in terms of market cap, Abbott Laboratories (NYSE:ABT) has a business model closer to that of Johnson & Johnson than most other pharmaceutical firms. Abbott shares followed a similar path as Merck & Co., Inc. (NYSE:MRK) — up more than 20% before falling. The stock is now up around 14% for the year.

Since J&J didn’t pull back as much as some of its peers, is it now much pricier as a result? Not necessarily.

Its trailing price-to-earnings multiple of below 24 stands very close to that of Merck. Pfizer Inc. (NYSE:PFE) and Abbott Laboratories (NYSE:ABT) have significantly lower trailing P/E values of less than 14 and 11, respectively. However, looking ahead paints a different picture.

Abbott’s forward P/E of almost 16 ranks as the highest of the four companies. J&J trails with a forward P/E a little under 15. Meanwhile, Pfizer and Merck both have forward multiples between 12 and 13. Factoring in these expectations of future earnings makes Johnson & Johnson stock look reasonably priced in comparison with the other stocks.

Wonderful

For investors looking at the long run, Johnson & Johnson is nearly always worth consideration. Just as Warren Buffett said when discussing the company’s mistakes in recent years, J&J has “a lot of wonderful products and it’s got a wonderful balance sheet.”

I’d throw in a wonderful dividend yield to that mix. J&J’s yield currently stands at 3.2%. Is the time ripe to buy Johnson & Johnson stock? The signs point to it being a wonderful time.

The article Is the Time Ripe to Buy Johnson & Johnson Stock? originally appeared on Fool.com and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Biotech Insider Alert - $6 Stock To Hit $40

$200 Million Dollar Healthcare Hedge Fund's #1 Best Idea Right Now

The best healthcare hedge fund out there right now is one of the largest shareholders in this biotech stock. The fund returned more than 20% in each of the last 2 years with a virtually fully hedged portfolio, and it's sending out a BUY signal on this biotech stock. Get your FREE REPORT today (retail value of $300)

This is a FREE report from Insider Monkey. Credit Card is NOT required.
Comments
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months. Our beta is only 1.2 (don't click this link if beating the market isn't important to you).

Lists

The World’s Most Famous Circuses

Best Hair Stylists

Most Popular NASCAR Drivers

The Best Romance Movies of all Time

The Most Wanted Drug Lords

The Oldest Money Managers

The Greatest Directors in the World

Largest Animals in the World

World’s Most Expensive Desserts

Best Selling Comic Books of All Time

A-list Actors who Sabotaged Their Career

Rappers With a College Degree

The Best Jazz Albums of all Time

The Most Influential Jazz Musicians

The World’s Most Famous Photographers

The Best Oscar-Winning Songs

Most Influential Choreographers Ever

Most Expensive Department Stores in the World

The Most Expensive Stolen Paintings in the World

The World’s Most Expensive Teas

Top Oscar Record Holders

The Most Expensive Flowers in the World

Countries With a Booming Film Industry

Most Expensive Cupcakes in the World

Uncommon European Escapes

The Most Stolen Artists in History

Best Travel Destinations in Australia

World’s Most Expensive Musical Instruments

World’s Most Famous Animals

Most Expensive Cakes in the World

Most Expensive Kosher Champagne in the World

Most Expensive Kosher Wine in the World

The Most Surprisingly Dark Fairy Tales

Most Popular Travel Destinations in Asia

The 10 Most Expensive Dresses Ever Worn to the Oscars

World’s Most Visited Art Museums

Best Countries for Photographers to Work in

Best Paid Jobs in the Film Industry

The Most Renowned Recovered Paintings Ever

Child Stars That Turned out Just Fine

Books That Were Banned in the Past Century

World’s Richest Dancers

Best Remedies against Bad Breath

Foods That Improve Your Skin Texture

Best-Selling Children’s Books of all Time

Foods That Boost Your Libido

Best-Selling Books of all Time

The Most Expensive Academy Awards Jewelry in History

Most Expensive Japanese Restaurant In New York City

The Best B-Boy Movies

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 129% in 2.5 years!! Wondering How?

Download a complete edition of our newsletter for free!